Fig. 1

Percentage of HFEM patients at baseline receiving galcanezumab (versus placebo) and shifting from HFEM status to LFEM status, or HFEM to VLFEM status at each month during the treatment period. Abbreviations: GMB, galcanezumab; HFEM, high-frequency episodic migraine; LFEM, low-frequency episodic migraine; n, number of patients who were categorized as HFEM at baseline with a baseline value and at least one post-baseline value recorded; VLFEM, very low-frequency episodic migraine. Note: The percentages shown in the figure are raw values at each month and treatment group. P values comparing galcanezumab vs placebo are from the following GLIMMIX model for repeated measures: Shift from HFEM to VLFEM indicator = baseline migraine headache days/month, treatment group, month, treatment x month interaction, and study indicator (EVOLVE-1 and EVOLVE-2)